Polly A. Murphy, D.V.M., Ph.D. , served as Chief Business Officer at Avadel Pharmaceuticals plc from May 2024 through Alkermes plc s acquisition of Avadel in February 2026. Prior to that, Dr. Murphy was Chief Business Officer at UroGen Pharma, Inc. from August 2020 through May 2024 and served in various leadership roles at Pfizer from September 2008 to August 2020, including as Vice President and Head of Early Commercial Development, Pfizer Oncology Business Unit, from January 2019 to August 2020, Vice President and Head of Global Marketing and Commercial Development, Pfizer Oncology Business Unit, from June 2017 to December 2018 and Vice President and Head of Strategy and Business Development for Pfizer China from November 2013 to May 2018. Prior to Pfizer, Dr. Murphy worked in the biopharmaceuticals industry or academia for more than 20 years. Since August 2020, Dr. Murphy has served on the board of directors of Atea Pharmaceuticals, Inc., a publicly held company. Dr. Murphy received her D.V.M. and Ph.D. from Iowa State University and her M.B.A. from Nova Southeastern University. Among other attributes, skills and qualifications, the Board believes Dr. Murphy is uniquely qualified to serve as a director based on her extensive experience in strategy, business development and commercialization within the pharmaceutical industry.